Core Viewpoint - Yiling Pharmaceutical has demonstrated strong core profitability indicators in its 2025 mid-term report, with a revenue of 4.04 billion yuan and a net profit of 669 million yuan, reflecting a year-on-year increase of 26.03% [1] Group 1: Financial Performance - The company has proposed a cash dividend of 3 yuan per 10 shares (including tax) as a way to reward shareholders [1] - Yiling's average annual R&D investment over the past three years has remained stable at 900 million yuan, ranking among the top three in the industry [1] - In 2024, R&D expenses are expected to account for 13.94% of revenue, significantly higher than the industry average [1] Group 2: Innovation and R&D - Yiling has maintained a stable innovation rhythm, with 1-2 new Class 1 traditional Chinese medicine (TCM) applications submitted for approval each year [2] - The company has successfully approved five Class 1 new drugs in the past five years, with four entering the medical insurance directory [2] - The recent approval of Qifang Nasal Congestion Tablets is expected to participate in national medical insurance negotiations by the end of the year, laying a foundation for future revenue growth [2] Group 3: International Expansion - Yiling's core theory of "Luo Disease" is transitioning from a "Chinese theory" to a "global topic," with clinical trials published in top international journals [3] - The company has registered and launched over ten TCM products in more than 50 countries and regions, translating international expansion into tangible sales [3] Group 4: Market Valuation - Despite Yiling's dual advantages of being an "innovative drug" and "international expansion" company, the market still values it using traditional TCM PE frameworks, failing to recognize its extensive R&D pipeline [4] - The estimated reasonable market value of Yiling is around 30 billion yuan, indicating a 20%-30% valuation discrepancy compared to current market consensus [4] - The ongoing policy support for TCM innovation and accelerated drug review processes present unprecedented development opportunities for Yiling [4]

Core Viewpoint - The "2025 Phoenix Star Listed Company Awards" ceremony was held in Guangzhou, recognizing companies for their performance in innovation, returns, responsibility, growth, brand influence, and globalization [1] Award Categories and Winners - The awards included categories such as Best Innovative Listed Company, Best Shareholder Return Listed Company, Most Socially Responsible Listed Company, Best Employer Award, Most Growth Potential Listed Company, Most Brand Influential Listed Company, Best Global Business Contribution Listed Company, Best Overseas Globalization Case, and Best IPO Company [1] - Six companies were awarded the title of "Most Brand Influential Listed Company": China Railway Construction Corporation, China Pacific Insurance, Guangzhou Baiyunshan Pharmaceutical, Yiling Pharmaceutical, Master Kong, and Haier Smart Home [1][3] Company Highlights - **China Railway Construction Corporation**: Recognized for its significant role in the "Belt and Road" initiative, operating in over 140 countries, and has been listed among the Fortune Global 500 for 19 consecutive years. The company emphasizes high-quality development and innovation in infrastructure [5][6] - **Master Kong**: Acknowledged for its long-term respect for consumers and commitment to quality. The company aims to promote Chinese culinary culture globally while focusing on technological upgrades and cultural heritage [8][9] - **China Pacific Insurance**: The company has a strong brand value and influence, providing comprehensive protection to 180 million customers. It has been ranked among the top five global insurance brands for several years [11] - **Guangzhou Baiyunshan Pharmaceutical**: As a World Fortune 500 company, it emphasizes high-quality products and social responsibility, with a brand value of 31.79 billion yuan, leading the pharmaceutical health sector in China [13] - **Haier Smart Home**: Transitioned from a home appliance leader to a smart living pioneer, serving over 1 billion users globally. The company focuses on technological innovation and sustainable development, holding the highest number of smart home invention patents for 13 consecutive years [15][16] - **Yiling Pharmaceutical**: Known for its innovative traditional Chinese medicine products, with 17 patented drugs, 11 of which are included in the national medical insurance directory. The company has successfully expanded its market presence in over 50 countries [17][18]

Core Viewpoint - The Chinese medicine sector is experiencing a mixed performance, with the leading Chinese medicine ETF (560080) showing resilience despite market fluctuations, attracting significant capital inflows and demonstrating strong growth potential in the context of regulatory changes and industry innovation efforts [1][4][6]. Market Performance - The Chinese medicine ETF (560080) recorded a slight decline but maintained a premium throughout the day, with a trading volume exceeding 71 million yuan. Over the past 10 days, it has seen net inflows on 9 occasions, totaling over 150 million yuan, and its latest scale has surpassed 2.4 billion yuan, leading its peers [1][4]. - Major components of the ETF index mostly experienced pullbacks, with Renhe Pharmaceutical declining over 1%, while Panlong Pharmaceutical rose over 1% [3][5]. Financing and Investment Trends - Leveraged funds are increasingly utilizing the ETF to invest in the high-value Chinese medicine consumer sector, with the latest financing balance approaching 80 million yuan and a financing buy-in amount exceeding 12 million yuan as of September 16, 2025 [4]. - The Chinese medicine industry is viewed as having stable cash flow and high dividends, with companies like Huaren Sanjiu and Jiangzhong Pharmaceutical showing strong performance in their incentive plans, which are expected to drive new growth [7][8]. Regulatory Developments - The National Medical Products Administration has announced new regulations for Chinese medicine production supervision, effective March 1, 2026, emphasizing quality control throughout the entire production process [5]. Innovation and Growth Strategies - Chinese medicine companies are actively pursuing innovation and transformation into chemical and biological pharmaceuticals through self-research, mergers and acquisitions, and strategic partnerships, aiming to create a second growth curve [6]. - The industry is expected to see improved performance in the second half of 2025, driven by reduced cost pressures from declining raw material prices and enhanced operational efficiencies [7][9]. Dividend and Profitability Insights - A significant number of central state-owned enterprises in the Chinese medicine sector are projected to have dividend yields exceeding 3% in 2024, with Jiangzhong Pharmaceutical and Dong'e Ejiao leading in dividend rates [8][9]. - Despite facing growth pressures in the first half of 2025, many companies have managed to achieve positive growth in net profit through quality improvement and efficiency enhancement strategies [9]. Market Sentiment and Future Outlook - The Chinese medicine index is gradually recovering, with institutional holdings remaining light. The sector is expected to attract more capital as it combines attributes of new consumer demand and pharmaceutical needs [10][12].

Core Viewpoint - Yiling Pharmaceutical is accelerating its international expansion, particularly in the anti-aging product sector, as evidenced by the positive reception from Brazilian media executives who are eager to introduce these products to the Brazilian market [1] Group 1: Company Strategy and Innovation - Yiling Pharmaceutical adheres to the principle of "inheritance and innovation" and employs a five-in-one innovative operational model that integrates theory, clinical practice, research, industry, and education, creating a virtuous cycle for sustainable development [3] - The company has established over 60 medicinal herb planting bases across more than 20 provinces in China to ensure high-quality raw materials, adhering to strict planting standards and management systems [5] Group 2: Quality Control and Research - Yiling Pharmaceutical's production facilities have passed international certifications, including those from the US and EU, and have implemented a comprehensive quality management system to ensure the safety and efficacy of its products [5] - The research team collaborates with top international medical research institutions, conducting high-standard evidence-based medical studies and publishing over 300 SCI papers, which validate the efficacy and safety of traditional Chinese medicine [5] Group 3: Brand Development and Market Penetration - The company has developed a systematic theory of "Luo Disease," which has garnered significant attention and multiple national awards, enhancing the brand's credibility and recognition in the international market [6] - Yiling Pharmaceutical has launched 17 patented traditional Chinese medicine products across various clinical fields, including cardiovascular, respiratory, endocrine, oncology, and aging, with a presence in over 50 countries and regions worldwide [7]

证券代码：002603 证券简称：以岭药业 公告编号：2025-037 石家庄以岭药业股份有限公司 2025 年第一次临时股东大会决议公告 （2）网络投票时间：2025 年 9 月 15 日。其中，通过深圳证券交易所交易 系统进行网络投票的时间为 2025 年 9 月 15 日上午 9:15—9:25，9:30—11:30，下 午 13:00—15:00；通过深圳证券交易所互联网投票系统投票的具体时间为 2025 年 9 月 15 日 9:15 至 15:00 的任意时间 2、会议地点：石家庄高新区天山大街 238 号以岭健康城会议室 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会没有涉及变更前次股东大会决议。 一、会议召开和出席情况 （一）会议召开情况： 1、会议召开时间： （1）现场会议时间：2025 年 9 月 15 日下午 14:50 3、会议召开方式：现场投票、网络投票相结合 4、会议召集人和主持人：公司董事会。董事长吴相君先生主持会议。 本次会议的召集、召开程序及表决方式符合有关 ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于石家庄以岭药业股份有限公司 2025 年第一次临时股东大会的 法律意见书 对本法律意见书的出具，本所律师特作如下声明： 1．本所律师仅就本次会议的召集与召开程序、召集人和出席现场会议人员资格、 会议表决程序及表决结果的合法性发表意见，不对本次会议所审议的议案内容及该等议 案所表述的事实或数据的真实性、准确性和完整性发表意见； 2．本所律师无法对网络投票过程进行见证，参与本次会议网络投票的股东资格、 网络投票结果均由相应的证券交易所交易系统和互联网投票系统予以认证； 国枫律股字[2025]A0449 号 致：石家庄以岭药业股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2025 年第一次临时股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下 ...

Core Viewpoint - The company held an online earnings briefing on September 15, where it addressed investor inquiries regarding product promotion, sales performance, and future strategies [1]. Group 1: Product Focus - The Ba Zi Bu Shen capsules received attention for their effectiveness, but consumers face challenges in understanding the product's target audience, usage methods, and side effects, prompting a call for increased promotional efforts [2]. - The company stated that Ba Zi Bu Shen capsules are developed based on the theory of Qi and are classified as OTC Class A drugs, with multiple studies confirming their positive effects on age-related diseases [2]. Group 2: Financial Performance - For the first half of 2025, the company reported a revenue of 4.04 billion yuan, a year-on-year decrease of 12.26%, while net profit attributable to shareholders rose by 26.03% to 669 million yuan [3]. - The net profit excluding non-recurring items increased by 27.08% to 641 million yuan, and the net cash flow from operating activities surged by 214.97% to 832 million yuan [3]. - The company emphasized that operational quality is improving and plans to leverage its "Seventh Five-Year" strategy to enhance management, R&D, and marketing for stable growth [3]. Group 3: Future Strategies - The company has established a subsidiary, Shanghai Yiling Pharmaceutical, to advance the development of biopharmaceutical products and enhance its competitive edge in this area [3]. - The company is monitoring policies related to the collection of traditional Chinese medicine in Hubei and plans to increase R&D investment to cultivate new products and expand market share [3]. - The year 2025 is identified as a critical year for the "Seventh Five-Year" plan, focusing on technological innovation, results transformation, and industry development to achieve annual operational and profit targets [3].

Financial Performance - In the first half of 2025, the company achieved a revenue of CNY 4.04 billion, a decrease of 12.26% year-on-year [6] - The net profit attributable to shareholders was CNY 669 million, an increase of 26.03% year-on-year [6] - The net profit excluding non-recurring items was CNY 641 million, up 27.08% year-on-year [6] - The net cash flow from operating activities was CNY 832 million, an increase of 214.97% year-on-year, indicating improved operational quality [4][6] Product Development and Research - The Baizi Bujin Capsule is an OTC Class A drug developed based on the theory of Qi and essence, aimed at anti-aging [5] - Research published in the journal Biomedicine & Pharmacotherapy (impact factor 7.42) confirmed that Baizi Bujin Capsule can improve memory and muscle endurance in aging mice, significantly reducing their DNA methylation age [3][5] - Clinical studies led by the Xiyuan Hospital of the China Academy of Chinese Medical Sciences demonstrated the capsule's effectiveness in improving symptoms of aging across various systems, including neurological and cardiovascular [3][5] Strategic Outlook - The company plans to continue its "Seventh Five-Year" strategic plan, focusing on high-quality industry development and enhancing operational management [5][7] - There is an emphasis on increasing research and development output and optimizing the marketing system to achieve steady growth [5][7] - The establishment of a subsidiary, Shanghai Yiling Pharmaceutical, aims to enhance the company's competitiveness in biopharmaceuticals [7][8] Market and Sales Strategy - The company is committed to increasing the promotion of Baizi Bujin Capsule to convert research advantages into sales advantages [8] - The company is monitoring policies related to centralized procurement and will adapt its strategies accordingly [8] - Future focus includes strengthening budget management and operational efficiency to enhance profitability [8]

Group 1 - The "People's Health Star" science popularization initiative aims to enhance public awareness and understanding of health management, particularly focusing on chronic disease prevention and management [1][3]. - The event featured expert-led lectures and practical health management advice, emphasizing the importance of scientific diet, exercise, medication adherence, and regular health monitoring [1][2]. - The initiative is supported by various organizations, including Yiling Pharmaceutical and Guizhou Yipin Pharmaceutical, which aim to create an integrated service model for safe medication, chronic disease management, and health promotion [3]. Group 2 - The event included health screenings such as carotid plaque detection and blood pressure monitoring, providing residents with direct access to health consultations from medical professionals [3][4]. - The initiative will continue to operate through a combination of online and offline activities, engaging numerous cities and health experts to improve chronic disease prevention and enhance the quality of life for patients [3].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002603 证券简称：以岭药业 公告编号：2025-036 石家庄以岭药业股份有限公司 关于参加2025年河北辖区上市公司投资者网上集体接待日暨2025年半年报集体业绩说明会的公告 为进一步加强与投资者的互动交流，石家庄以岭药业股份有限公司（以下简称"公司"）将参加由河北省 上市公司协会联合深圳市全景网络有限公司举办的"2025年河北辖区上市公司投资者网上集体接待日暨 2025年半年报集体业绩说明会"活动，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信 公众号：全景财经，或下载全景路演 APP，参与本次互动交流，活动时间为 2025 年9月15日（周一） 15:00-17:00。届时公司董事长、总经理吴相君，董事、董事会秘书吴瑞，董事、财务负责人李晨光将在 线就公司业绩、公司治理、发展战略、经营状况和可持续发展等投资者关心的问题，与投资者进行沟通 与交流，欢迎广大投资者踊跃参与！ 特此公告。 石家庄以岭药业股份有限公司董事会 2025年9月11日 本公司及董 ...